Literature DB >> 7742293

Symmetrical lymphomatoid papulosis masquerading as pyoderma chancriformis of the eyelids.

J E Boulton, J R Chesterton, D H McGibbon.   

Abstract

Entities:  

Mesh:

Year:  1995        PMID: 7742293      PMCID: PMC505111          DOI: 10.1136/bjo.79.4.391-a

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  7 in total

1.  Pyodermia chancriformis faciei.

Authors:  W FRAIN-BELL
Journal:  Br J Dermatol       Date:  1957-01       Impact factor: 9.302

2.  Follicular lymphomatoid papulosis.

Authors:  L Requena; M Sánchez; S Coca; E Sánchez Yus
Journal:  Am J Dermatopathol       Date:  1990-02       Impact factor: 1.533

3.  Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign--histologically malignant.

Authors:  W L Macaulay
Journal:  Arch Dermatol       Date:  1968-01

Review 4.  The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas.

Authors:  R C Beljaards; R Willemze
Journal:  Br J Dermatol       Date:  1992-06       Impact factor: 9.302

5.  Follicular lymphomatoid papulosis.

Authors:  F M Sexton; J C Maize
Journal:  Am J Dermatopathol       Date:  1986-12       Impact factor: 1.533

Review 6.  Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment.

Authors:  R Willemze; R C Beljaards
Journal:  J Am Acad Dermatol       Date:  1993-06       Impact factor: 11.527

Review 7.  Lymphomatoid papulosis.

Authors:  D L Karp; T D Horn
Journal:  J Am Acad Dermatol       Date:  1994-03       Impact factor: 11.527

  7 in total
  1 in total

1.  Spectrum of CD30+ lymphoid proliferations in the eyelid lymphomatoid papulosis, cutaneous anaplastic large cell lymphoma, and anaplastic large cell lymphoma.

Authors:  R Krishna Sanka; Ralph C Eagle; Ted H Wojno; Kenneth R Neufeld; Hans E Grossniklaus
Journal:  Ophthalmology       Date:  2009-12-06       Impact factor: 12.079

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.